Literature DB >> 3956209

Confidence intervals following group sequential tests.

M N Chang, P C O'Brien.   

Abstract

A procedure is proposed for obtaining confidence intervals for the probability of response following completion of a group sequential phase II trial. Numerical examples showed that, by ordering the sample space using the likelihood principle, we are able to shorten the length of the intervals and to obtain more accurate coverage of probability relative to previously proposed methods. The method may also be used for interval estimation following phase III trials.

Mesh：

Year:  1986        PMID： 3956209     DOI： 10.1016/0197-2456(86)90004-8

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN： 0197-2456


  8 in total

Review 1.  Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.

Authors:  Sin-Ho Jung
Journal:  Contemp Clin Trials       Date:  2015-03-03       Impact factor: 2.226

2.  A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study.

Authors:  Orren Beaty; Stacey Berg; Susan Blaney; Marcio Malogolowkin; Mark Krailo; Ronald Knight; Paula Schaiquevich; Clinton Stewart; Zhengjia Chen; Marvin Nelson; Stephan Voss; S Percy Ivy; Peter C Adamson
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

3.  A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group.

Authors:  Murali M Chintagumpala; Henry S Friedman; Clinton F Stewart; James Kepner; Roger E McLendon; Paul L Modrich; Charles McCluggage; Peter Burger; Emi Holmes; Stephen Thompson; James Rutka; Jeff Michalski; Shiao Woo; Susan M Blaney; Larry E Kun; Marc E Horowitz
Journal:  J Neurooncol       Date:  2006-04       Impact factor: 4.130

4.  A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Timothy C Griffin; Sheila Weitzman; Howard Weinstein; Myron Chang; Mitchell Cairo; Robert Hutchison; Bruce Shiramizu; Joseph Wiley; Deborah Woods; Margaret Barnich; Thomas G Gross
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

5.  Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.

Authors:  Steven G DuBois; Mark D Krailo; Stephen L Lessnick; Richard Smith; Zhengjia Chen; Neyssa Marina; Holcombe E Grier; Kimberly Stegmaier
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

6.  A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study.

Authors:  J R Geyer; F M Balis; M D Krailo; R Heideman; E Broxson; J K Sato; D Poplack; W A Bleyer
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

7.  Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study.

Authors:  John F Kuttesch; Mark D Krailo; Timothy Madden; Mary Johansen; Archie Bleyer
Journal:  Pediatr Blood Cancer       Date:  2009-10       Impact factor: 3.167

8.  Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.

Authors:  Junjun Zhao; Menggang Yu; Xi-Ping Feng
Journal:  BMC Med Res Methodol       Date:  2015-06-07       Impact factor: 4.615
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.